1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Holly LaFon
Holly LaFon
Articles (8689)  | Author's Website |

Bernard Horn Comments on Teva Pharmaceutical

Guru stock highlight

April 16, 2018 | About:
Teva Pharmaceutical (NYSE:TEVA) continued to face headwinds, with sluggish generic product introductions and pricing pressures. With a new CEO at the helm, Teva launched a comprehensive restructuring plan to shore up its balance sheet. The company enacted layoffs and plant closures, optimized its generics portfolio and reviewed of its R&D and drug pipeline. Consistent with this agenda, Teva announced the termination of its CGRP migraine drug discovery and development pact with Sosei. The company also renegotiated some of its debt at much higher interest rates than previous. Neither of these actions was well received by the market.

From Bernard Horn (Trades, Portfolio)'s first quarter 2018 shareholder letter.

About the author:

Holly LaFon
I'm a financial journalist with a master of science in journalism from Medill at Northwestern University.

Visit Holly LaFon's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Holly LaFon


User Generated Screeners


Yamil BerardTepper's Leisure
jtepper2GrowthHighROC
gluon71gm-buylist-4
gluon71gm-buylist-3
DBrizancdn 18Jul2018 1249p
DBrizancdn 18Jul2018 1248p
HOLKLSUTop 20 Group 2018 All Sectors
DBrizancdn 18Jul2018 1219p
averacjrgood beta in up market
Nightdoc2S&P 500 quality
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK